Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).

N, Marx; J, Rosenstock; SE, Kahn; B, Zinman; JJ, Kastelein; JM, Lachin; MA, Espeland; E, Bluhmki; M, Mattheus; B, Ryckaert; S, Patel; OE, Johansen; HJ, Woerle

doi:10.1177/1479164115570301

Public

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).

Shared by NobleBlocks on Mar 15, 2015 • 12:00 AM UTC

Authors:

Marx N

Rosenstock J

Kahn SE

Abstract

CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovascular impact of linagliptin...

Subject

Type 2 diabetes

Cardiovascular Complications

Macrovascular

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!